Overview of the MINDACT trial results presented at EBCC-12
Published: 16 Oct 2020
Views: 114
Prof Etienne Brain - EORTC Breast cancer group chair
Prof Etienne Brain discusses with ecancer the results of the MINDACT trial presented at EBCC-12.
He talks about the importance of this trail and why it was initiated in the first place and how the long term follow-up has proved successful in using certain drug combinations for chemotherapy against breast cancer.
He says age is also a factor that impacts the type and prognosis of chemotherapy used.
Related Videos
Highlights from EBCC-12
Prof Nadia Harbeck - EBCC Conference Chair
23 Oct 2020
Breast cancer roundup from ESMO 2020
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
23 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
Update from KAITLIN for high-risk HER2-positive early breast cancer
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associate...
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
7 Oct 2019
Melanoma highlights from ESMO 2019
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
30 Sep 2019
Role of chemotherapy in the treatment of metastatic breast cancer patients
Professors Joseph Gligorov, Yen-Shen Lu, Chris Twelves and Dr Reshma Mahtani
10 Dec 2018
